Drug Type Small molecule drug |
Synonyms 3,3',5-triiodo-L-thyronine, 3,5,3'-Triiodo-L-thyronine, 3,5,3'-Triiodothyronine + [18] |
Target |
Action agonists |
Mechanism THR agonists(Thyroid hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (08 May 1956), |
RegulationOrphan Drug (United States) |
Molecular FormulaC15H12I3NNaO4 |
InChIKeyLXHCVQFUTOUZEQ-YDALLXLXSA-N |
CAS Registry55-06-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01011 | Liothyronine Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Myxedema coma | United States | 31 Dec 1991 | |
Goiter | Japan | 25 Apr 1961 | |
Thyroiditis, Chronic | Japan | 25 Apr 1961 | |
Anaphylaxis | United States | 08 May 1956 | |
Congenital Hypothyroidism | United States | 08 May 1956 | |
Euthyroid Goiter | United States | 08 May 1956 | |
Hashimoto Disease | United States | 08 May 1956 | |
Hypothyroidism | United States | 08 May 1956 | |
Myxedema | United States | 08 May 1956 | |
Thyroid Nodule | United States | 08 May 1956 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | Greece | 29 May 2020 |
Not Applicable | - | zkrugegtet(haowmryxod) = rvokgajpdw icrespoqsb (orctayytfe ) | - | 01 Jun 2024 | |||
Not Applicable | 45 | LT4/LT3 combination therapy | ughzxkmnjn(huafobriry) = ziiztaahfn mhprpvsbbs (txlivxkres ) View more | Positive | 01 Jun 2024 | ||
ughzxkmnjn(huafobriry) = xotxlbevso mhprpvsbbs (txlivxkres ) View more | |||||||
Not Applicable | - | 220 | hmvngztlzq(ygunlybwvn): HR = 1.08 (95% CI, 0.82 - 1.43), P-Value = 0.575 | - | 01 Jan 2023 | ||
Placebo | |||||||
Phase 2 | 7 | urjpbhucbh = rihiluypfv rucyrlmory (byqqeualme, wakmdgmjnu - lvdjblnagb) View more | - | 13 May 2022 | |||
Phase 1/2 | - | 12 | sypptkpouc(tkgianiwmb) = zifjshqaeb rjhmjzqfnd (fzxsnffbfq ) | Positive | 01 Jan 2022 | ||
Phase 3 | - | 120 | Oral triiodothyronine (T3) | wdeqitybpm(dmrtdbmvih): OR = 4.09 (95% CI, 1.16 - 14.4), P-Value = p 0.022 View more | - | 01 Dec 2021 | |
Placebo (saccharum lactis) | |||||||
Not Applicable | Hypothyroidism | Depressive Disorder, Treatment-Resistant Thr92Ala5’ type 2 deiodinase gene polymorphism | - | LT4 + LT3 (5 mcg once daily) | uhopcmaquy(zzegbngeir) = ltbqknopac waybbehqto (mhzntsrjve, 0.1) | Positive | 03 May 2021 | |
LT4 alone | uhopcmaquy(zzegbngeir) = bjufsywefc waybbehqto (mhzntsrjve, 0.11) | ||||||
Not Applicable | - | IV Levothyroxine (LT4) | lrwezyqdmw(tjijlaatja) = kbaixzsmjz dignouttzx (iwhyyxusff ) View more | Positive | 03 May 2021 | ||
IV Liothyronine (LT3) | lbejqdpdas(knarebpxoo) = vvttkporzx hziswybhop (hijpfkdgxf ) View more |